Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 10166191 Sustained-release dosage forms of ruxolitinib

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Date Filed
November 14, 2013
Date of Patent
January 1, 2019
Patent Applicant
Incyte
Incyte
Patent Application Number
14079901
Patent Citations Received
‌
US Patent 12071439 Process and intermediates for preparing a JAK inhibitor
0
‌
US Patent 11833152 JAK1 pathway inhibitors for the treatment of cytokine-related disorders
0
‌
US Patent 11905292 Process and intermediates for preparing a JAK inhibitor
0
‌
US Patent 11957661 JAK1 pathway inhibitors for the treatment of vitiligo
0
‌
US Patent 11510923 Ruxolitinib formulation for reduction of itch in atopic dermatitis
‌
US Patent 10874616 Sustained-release dosage forms of ruxolitinib
‌
US Patent 11576865 Sustained-release dosage forms of ruxolitinib
‌
US Patent 11576864 Sustained-release dosage forms of ruxolitinib
‌
US Patent 11584961 Biomarkers for inflammatory skin disease
‌
US Patent 11045421 Sustained release dosage forms for a JAK1 inhibitor
•••
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
10166191
Patent Primary Examiner
‌
Umamaheswari Ramachandran

Find more entities like US Patent 10166191 Sustained-release dosage forms of ruxolitinib

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.